Clinical Trial Detail

NCT ID NCT04194944
Title A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer (LIBRETTO-431)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Eli Lilly and Company
Indications

lung non-squamous non-small cell carcinoma

Therapies

Cisplatin + Pemetrexed Disodium

Carboplatin + Pemetrexed Disodium

Selpercatinib

Carboplatin + Pembrolizumab + Pemetrexed Disodium

Cisplatin + Pembrolizumab + Pemetrexed Disodium

Age Groups: adult senior

Additional content available in CKB BOOST